Literature DB >> 21263446

Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.

M Masiero1, S Minuzzo, I Pusceddu, L Moserle, L Persano, V Agnusdei, V Tosello, G Basso, A Amadori, S Indraccolo.   

Abstract

Activation of the Notch pathway occurs commonly in T acute lymphoblastic leukemia (T-ALL) because of mutations in Notch1 or Fbw7 and is involved in the regulation of cell proliferation and survival. Deregulated Notch3 signalling has also been shown to promote leukemogenesis in transgenic mice, but the targets of Notch3 in human T-ALL cells remain poorly characterized. Here, we show that Notch3 controls levels of mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1). In a model of T-ALL cell dormancy, both Notch3 activation and MKP-1 expression were upregulated in aggressive compared with dormant tumors, and this inversely correlated with the levels of phosphorylated p38 and extracellular signal-regulated kinase1/2 (ERK1/2) MAPKs, two canonical MKP-1 targets. We demonstrate that MKP-1 protein levels are regulated by Notch3 in T-ALL cell lines because its silencing by RNA interference or treatment with γ-secretase inhibitors induced strong MKP-1 reduction whereas activation of Notch3 signalling had the opposite effect. Furthermore, MKP-1 has an important role in T-ALL cell survival because its attenuation by short hairpin RNA significantly increased cell death under stress conditions. This protective function has a key role in vivo, as MKP-1-deficient cells showed impaired tumorigenicity. These results elucidate a novel mechanism downstream of Notch3 that controls the survival of T-ALL cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263446     DOI: 10.1038/leu.2010.323

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  25 in total

Review 1.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

2.  Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sibasish Dolai; Cristina Delgado-Martin; Tiffaney Vincent; Alissa Robbins; Arthavan Selvanathan; Theresa Ryan; Junior Hall; Andrew C Wood; Sarah K Tasian; Stephen P Hunger; Mignon L Loh; Charles G Mullighan; Brent L Wood; Michelle L Hermiston; Stephan A Grupp; Richard B Lock; David T Teachey
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

Review 3.  Mechanisms of disseminated cancer cell dormancy: an awakening field.

Authors:  María Soledad Sosa; Paloma Bragado; Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2014-08-14       Impact factor: 60.716

Review 4.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

5.  Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy.

Authors:  Heiko Enderling; Philip Hahnfeldt; Lynn Hlatky; Nava Almog
Journal:  Cancer Res       Date:  2012-03-13       Impact factor: 12.701

6.  Zebrafish screen identifies novel compound with selective toxicity against leukemia.

Authors:  Suzanne Ridges; Will L Heaton; Deepa Joshi; Henry Choi; Anna Eiring; Lance Batchelor; Priya Choudhry; Elizabeth J Manos; Hossein Sofla; Ali Sanati; Seth Welborn; Archana Agarwal; Gerald J Spangrude; Rodney R Miles; James E Cox; J Kimble Frazer; Michael Deininger; Kaveri Balan; Matthew Sigman; Markus Müschen; Tatiana Perova; Radia Johnson; Bertrand Montpellier; Cynthia J Guidos; David A Jones; Nikolaus S Trede
Journal:  Blood       Date:  2012-04-09       Impact factor: 22.113

7.  Drugging DNA repair to target T-ALL cells.

Authors:  Yashodhara Dasgupta; Konstantin Golovine; Margaret Nieborowska-Skorska; Li Luo; Ksenia Matlawska-Wasowska; Charles G Mullighan; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2017-11-08

8.  Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.

Authors:  V Agnusdei; S Minuzzo; C Frasson; A Grassi; F Axelrod; S Satyal; A Gurney; T Hoey; E Seganfreddo; G Basso; S Valtorta; R M Moresco; A Amadori; S Indraccolo
Journal:  Leukemia       Date:  2013-06-18       Impact factor: 11.528

9.  Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors.

Authors:  James D Phelan; Ingrid Saba; Hui Zeng; Christian Kosan; Malynda S Messer; H Andre Olsson; Jennifer Fraszczak; David A Hildeman; Bruce J Aronow; Tarik Möröy; H Leighton Grimes
Journal:  PLoS Genet       Date:  2013-09-12       Impact factor: 5.917

10.  Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas.

Authors:  Runchun Lu; Hua Gao; Hongyun Wang; Lei Cao; Jiwei Bai; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.